SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock.

SABS has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of SAB Biotherapeutics in a report on Wednesday. Craig Hallum started coverage on SAB Biotherapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Stock Up 10.1 %

SABS stock traded up $0.21 during midday trading on Wednesday, reaching $2.28. The stock had a trading volume of 578,489 shares, compared to its average volume of 179,638. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a 52-week low of $2.01 and a 52-week high of $6.30. The firm has a fifty day simple moving average of $3.63 and a two-hundred day simple moving average of $3.13.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%. On average, research analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in SAB Biotherapeutics stock. HB Wealth Management LLC increased its holdings in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 118.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 237,400 shares of the company’s stock after purchasing an additional 128,800 shares during the period. HB Wealth Management LLC owned 2.57% of SAB Biotherapeutics worth $982,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.